Payment overview · 2025
General Payments
$6,977.79
186 reported records · 26 companies
Healthcare provider profile · identity verified
Sashi Kumar Makam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW WINDSOR, NY · NPI 1861494908
Verified facts
What the public records show
CMS Open Payments records show Sashi Kumar Makam, MD received $6,977.79 in general payments during 2025 across 186 reported records.
PFIZER INC. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $2,564.45 | 36.8% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $884.14 | 12.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $347.11 | 5.0% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $323.89 | 4.6% | 20 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $316.63 | 4.5% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $302.31 | 4.3% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $270.82 | 3.9% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $260.36 | 3.7% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $213.11 | 3.0% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $192.10 | 2.8% | 8 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $168.92 | 2.4% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.42 | 2.2% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $147.20 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $143.91 | 2.1% | 9 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $125.00 | 1.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $125.00 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $97.86 | 1.4% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $64.98 | 0.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.05 | 0.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.61 | 0.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.36 | 0.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.11 | 0.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $32.66 | 0.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.42 | 0.3% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.82 | 0.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.55 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,637.79 | 185 |
| Consulting Fee | $2,340.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $746.74 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $472.10 | 24 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $302.31 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $205.33 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $176.01 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $176.01 | 12 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $168.92 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $156.29 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.29 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $153.29 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $152.30 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $147.20 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $145.80 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $143.91 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $130.75 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $123.88 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.15 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.23 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $102.22 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $97.86 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.32 | 5 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $89.23 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.30 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $64.98 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.10 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.05 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $40.58 | 5 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 179 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
179 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
179 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 865 | 247 |
| Losartan Potassium | Losartan Potassium | 471 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 87 |
| Metformin Hcl | Metformin Hcl | 273 | 86 |
| Simvastatin | Simvastatin | 266 | 80 |
| Omeprazole | Omeprazole | 262 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 63 |
| Gabapentin | Gabapentin | 217 | 69 |
| Furosemide | Furosemide | 200 | 70 |
| Glimepiride | Glimepiride | 195 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 53 |
| Jardiance | Empagliflozin | 179 | 43 |
| Lisinopril | Lisinopril | 179 | 53 |
| Ezetimibe | Ezetimibe | 171 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 42 |
| Ozempic | Semaglutide | 136 | 30 |
| Alprazolam | Alprazolam | 125 | 32 |
| Trazodone Hcl | Trazodone Hcl | 124 | 28 |
| Allopurinol | Allopurinol | 121 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 20 |
| Famotidine | Famotidine | 105 | 27 |
| Eliquis | Apixaban | 102 | 36 |
| Farxiga | Dapagliflozin Propanediol | 100 | 25 |
| Carvedilol | Carvedilol | 97 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 27 |
| Meloxicam | Meloxicam | 96 | 32 |
| Ramipril | Ramipril | 92 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 24 |
| Bupropion Xl | Bupropion Hcl | 87 | 21 |
| Azithromycin | Azithromycin | 86 | 70 |
| Enalapril Maleate | Enalapril Maleate | 84 | 22 |
| Amoxicillin | Amoxicillin | 83 | 60 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 22 |
| Valsartan | Valsartan | 79 | 26 |
| Mounjaro | Tirzepatide | 77 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 15 |
| Mirtazapine | Mirtazapine | 63 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 13 |
| Methylprednisolone | Methylprednisolone | 59 | 49 |
| Metformin Hcl Er | Metformin Hcl | 58 | 21 |
| Tramadol Hcl | Tramadol Hcl | 58 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Prednisone | Prednisone | 49 | 18 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Sertraline Hcl | Sertraline Hcl | 43 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Januvia | Sitagliptin Phosphate | 41 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Torsemide | Torsemide | 38 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 25 |
| Finasteride | Finasteride | 37 | 12 |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 26 |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 23 |
| Diazepam | Diazepam | 35 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 20 |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | 11 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Naproxen | Naproxen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Matzim La | Diltiazem Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,977.79 · 186 records | PFIZER INC. | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, Fabhalta, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, LOREEV XR, Leqembi, MINIMED 780G, MOUNJARO, NUCALA, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, TEZSPIRE, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, YUPELRI, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error